State Street
IMVT icon

State Street’s Immunovant IMVT Stock Holding History

State Street’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$113M Buy
4,537,929
+751,003
+20% +$19.4M ﹤0.01% 1312
2025
Q4 		$96.3M Buy
3,786,926
+894,308
+31% +$19.9M ﹤0.01% 1383
2025
Q3 		$46.6M Buy
2,892,618
+62,544
+2% +$1.01M ﹤0.01% 1755
2025
Q2 		$45.3M Sell
2,830,074
-257,021
-8% -$3.89M ﹤0.01% 1728
2025
Q1 		$52.8M Buy
3,087,095
+389,573
+14% +$8.15M ﹤0.01% 1597
2024
Q4 		$66.8M Sell
2,697,522
-324,820
-11% -$9.21M ﹤0.01% 1573
2024
Q3 		$86.2M Buy
3,022,342
+303,386
+11% +$8.95M ﹤0.01% 1410
2024
Q2 		$71.8M Sell
2,718,956
-922,951
-25% -$26.3M ﹤0.01% 1461
2024
Q1 		$118M Buy
3,641,907
+425,531
+13% +$15.5M 0.01% 1205
2023
Q4 		$136M Sell
3,216,376
-252,241
-7% -$9.28M 0.01% 1094
2023
Q3 		$133M Buy
3,468,617
+234,448
+7% +$5.3M 0.01% 995
2023
Q2 		$61.4M Sell
3,234,169
-733,436
-18% -$13.7M ﹤0.01% 1534
2023
Q1 		$61.5M Buy
3,967,605
+854,662
+27% +$14.8M ﹤0.01% 1506
2022
Q4 		$55.3M Buy
3,112,943
+2,234,342
+254% +$28.1M ﹤0.01% 1558
2022
Q3 		$4.9M Sell
878,601
-14,079
-2% -$68.8K ﹤0.01% 3071
2022
Q2 		$3.48M Buy
892,680
+56,938
+7% +$246K ﹤0.01% 3272
2022
Q1 		$4.61M Sell
835,742
-1,947,052
-70% -$12.1M ﹤0.01% 3222
2021
Q4 		$23.7M Sell
2,782,794
-1,329,000
-32% -$11M ﹤0.01% 2347
2021
Q3 		$35.7M Sell
4,111,794
-278,843
-6% -$2.52M ﹤0.01% 2045
2021
Q2 		$46.4M Buy
4,390,637
+774,877
+21% +$10.8M ﹤0.01% 1901
2021
Q1 		$58M Buy
3,615,760
+1,746,740
+93% +$46.1M ﹤0.01% 1631
2020
Q4 		$86.3M Buy
1,869,020
+717,555
+62% +$33.2M 0.01% 1259
2020
Q3 		$40.5M Buy
1,151,465
+819,890
+247% +$24.7M ﹤0.01% 1606
2020
Q2 		$8.07M Buy
+331,575
New +$7.11M ﹤0.01% 2537

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street's IMVT Position: Q1 2026 in Review

State Street increased its Immunovant (IMVT) stake by 20% in Q1 2026, buying an estimated $19.4M and bringing the position to 4,537,929 shares worth $113M. The position accounts for ﹤0.01% of the portfolio, ranked #1312.

State Street first reported a position in IMVT in Q2 2020 and has held it in 24 quarters since. The position peaked at $136M in Q4 2023. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • State Street held 4,537,929 shares of Immunovant worth $113M as of Q1 2026.
  • State Street bought 751,003 Immunovant shares in Q1 2026, an estimated $19.4M.
  • Immunovant made up ﹤0.01% of State Street's portfolio in Q1 2026, its #1312 holding.
  • State Street first reported a position in Immunovant in Q2 2020 and has held it in 24 quarters since.
  • State Street's Immunovant position peaked at $136M in Q4 2023.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.